Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07355361
NCT07355361
Not yet recruiting
Phase 2

Multicenter, Randomized, Parallel-Controlled Clinical Trial on Huaier Granule for Proteinuria Associated With Immunotherapy and Anti-Angiogenic Therapy in Breast Cancer Patients

Fudan University0 sites120 target enrollmentStarted: January 15, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Not yet recruiting
Enrollment
120
OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment.

The main question it aims to answer is:

* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks?

Researchers will compare the group receiving standard care plus Huaier Granule to the group receiving standard care alone to see if the combination is more effective at reducing protein levels in the urine.

Participants will:

  • Be randomly assigned to one of the two study groups.
  • Continue their prescribed anti-cancer therapy (immunotherapy or anti-angiogenic therapy).
  • Receive standard medical care for proteinuria from a kidney specialist.
  • If in the experimental group, take Huaier Granule orally, three times a day.
  • Attend clinic visits every 4 weeks for up to 24 weeks for check-ups and tests, including urine and blood tests.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •\*\*Inclusion Criteria\*\*
  • •Female patients aged 18-75 years.
  • •Histopathologically confirmed diagnosis of breast cancer.
  • •Currently receiving or having a prior history of immunotherapy and/or anti-angiogenic therapy.
  • •First-time detection of proteinuria on urinalysis, graded as +, ++, or +++.
  • •24-hour urinary protein quantification between 0.15g and 3.5g (exclusive).
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
  • •Karnofsky Performance Status (KPS) score ≥
  • •No prior treatment with Huaier Granule within one month before enrollment.
  • •Life expectancy of at least 6 months.

Exclusion Criteria

  • •\*\*Exclusion Criteria\*\*
  • •Known history of chronic kidney disease (eGFR \<60 ml/min/1.73m²) or diabetic nephropathy.
  • •Proteinuria attributed to other diseases, including but not limited to primary renal disease, hypertension, urinary tract infection, systemic lupus erythematosus, or multiple myeloma.
  • •Current use of ACEI/ARB medications (unless the dosage has been stable for ≥4 weeks prior to enrollment).
  • •Known allergy, contraindication, or specific precaution to any component of Huaier Granule.
  • •Women who are pregnant, breastfeeding, or planning to conceive.
  • •Concurrent participation in any other clinical trial investigating medications for proteinuria.
  • •Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in this study.

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Zhimin Shao

Director of Breast Surgery Department

Fudan University

Similar Trials

Enrolling By Invitation
Phase 3
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
NCT07348575Second Affiliated Hospital of Nanchang University80
Not yet recruiting
Phase 3
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
NCT07355283ImmuneOnco Biopharmaceuticals (Shanghai) Inc.198
Not yet recruiting
Phase 2
A Phase II/III Randomized Double-Blind Multicenter Study Comparing UC-MSC-Derived Secretome and Sodium Hyaluronate in Patients With Knee Osteoarthritis
NCT07337863Universitas Sriwijaya50
Not yet recruiting
Phase 2
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
NCT07347444Fudan University48
Recruiting
Phase 2
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT07311200InventisBio Co., Ltd120